Physician profile
Frederic A Rawlins
NPI 1205889193
$1,818.80
in general payments reported to CMS, 2019-2025
20 companies · $563 in 2025
The $563 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.81 · 2023: $323 · 2024: $920 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.02 |
| Education | $231.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $654.36 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $231.97 | 2023-2025 | |
| Genzyme Corporation | $210.20 | 2023-2024 | |
| Glaxosmithkline, LLC. | $115.01 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| La Jolla Pharmaceutical Company | $107.98 | 2024-2025 | Giapreza |
| Genentech USA, INC. | $74.88 | 2025 | Xolair |
| Ethicon INC. | $65.53 | 2023 | Monarch Platform |
| Mylan Specialty L.P. | $50.50 | 2023-2024 | Yupelri |
| Electromed, INC. | $49.69 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $37.14 | 2023-2024 | Fasenra |
| Mallinckrodt Hospital Products INC. | $34.28 | 2024-2025 | Terlivaz, Acthar |
| Regeneron Healthcare Solutions, INC. | $30.85 | 2025 | Dupixent |
| Inogen, INC. | $23.72 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $22.10 | 2025 | Zerbaxa |
| Harmony Biosciences LLC | $21.36 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $20.92 | 2024 | Lumryz |
| Lilly USA, LLC | $19.09 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $18.57 | 2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $17.84 | 2024 | Uptravi |
| Veran Medical Technologies, INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Rawlins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.